T1	Participants 0 75	Long-term effects of risperidone in children with autism spectrum disorders
T2	Participants 125 275	short-term benefit of risperidone in ameliorating severe disruptive behavior in pediatric patients with autism spectrum disorders is well established;
T3	Participants 363 432	Thirty-six children with an autism spectrum disorder (5-17 years old)
T4	Participants 513 557	8-week open-label treatment with risperidone
T5	Participants 856 949	a significant deterioration of symptoms based on clinical judgment and a parent questionnaire
T6	Participants 1018 1116	this occurred in 3 of 12 patients continuing on risperidone versus 8 of 12 who switched to placebo
T7	Participants 1243 1421	This study indicates the effectiveness of risperidone during a period of several months, reducing disruptive behavior in about half of the children with autism spectrum disorders
T8	Participants 1481 1575	risperidone beyond 6 months, although considerable weight gain can limit the use of this agent
